Lifestyle management is the cornerstone of both primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and the importance of lifestyle management is emphasised by all major guidelines. Despite this, actual implementation of lifestyle management is poor. Lifestyle modification includes smoking cessation, weight loss, dietary change, increasing physical inactivity, and stress management. This review summarises evidence-based opportunities and challenges for healthcare professionals to promote healthy lifestyles at an individual level for the prevention of ASCVD.
AchtergrondIn Nederland wonen steeds meer zorgbehoeftige mensen thuis. Hieronder vallen mensen met het syndroom van Korsakov. Tot op heden mist een best-practice werkwijze voor goede zorg in de thuissituatie voor deze groep mensen.MethodeGedurende twee netwerkbijeenkomsten hebben zorgprofessionals, mantelzorgers en experts van het Korsakov Kenniscentrum ervaringen gedeeld met betrekking tot extramurale zorg voor mensen met het syndroom van Korsakov. Vervolgens is in de literatuur gezocht naar bruikbare handvatten voor goede extramurale zorg.ResultatenZorgverleners werkzaam in de intra- en extramurale zorg voor mensen met het syndroom van Korsakov voelen zich tekortschieten ten opzichte van mantelzorgers en cliënten, omdat onvoldoende specialistische extramurale zorg voor mensen met het syndroom van Korsakov beschikbaar is of ze onzekerheid ervaren wanneer het gaat om de handelwijze in de extramurale zorgverlening. Het gebrek aan handvatten maakt de spanningen in de extramurale zorgsituatie groot. Uit de literatuur blijkt dat de in de praktijk bestaande werkwijzen niet voldoende aansluiten bij de specialistische problematiek behorende bij het syndroom van Korsakov.ConclusieVervolgonderzoek is nodig dat gericht is op het ontwikkelen van werkwijzen in de extramurale zorg voor mensen met het syndroom van Korsakov. Hierbij dient het ontwikkelen van professionele steunstructuren in deze extramurale zorg centraal te staan.
MULTIFILE
Introduction Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50–65% of patients undergoing RC experience perioperative complications. The risk, severity and impact of these complications is associated with a patient’s preoperative cardiorespiratory fitness, nutritional and smoking status and presence of anxiety and depression. There is emerging evidence supporting multimodal prehabilitation as a strategy to reduce the risk of complications and improve functional recovery after major cancer surgery. However, for bladder cancer the evidence is still limited. The aim of this study is to investigate the superiority of a multimodal prehabilitation programme versus standard-of-care in terms of reducing perioperative complications in patients with bladder cancer undergoing RC.Methods and analysis This multicentre, open label, prospective, randomised controlled trial, will include 154 patients with bladder cancer undergoing RC. Patients are recruited from eight hospitals in The Netherlands and will be randomly (1:1) allocated to the intervention group receiving a structured multimodal prehabilitation programme of approximately 3–6 weeks, or to the control group receiving standard-of-care. The primary outcome is the proportion of patients who develop one or more grade ≥2 complications (according to the Clavien-Dindo classification) within 90 days of surgery. Secondary outcomes include cardiorespiratory fitness, length of hospital stay, health-related quality of life, tumour tissue biomarkers of hypoxia, immune cell infiltration and cost-effectiveness. Data collection will take place at baseline, before surgery and 4 and 12 weeks after surgery.Ethics and dissemination Ethical approval for this study was granted by the Medical Ethics Committee NedMec (Amsterdam, The Netherlands) under reference number 22–595/NL78792.031.22. Results of the study will be published in international peer-reviewed journals.Trial registration number NCT05480735.